Evidence map›Paper›PMID 37232832›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Predictors of Prostate Cancer at Fusion Biopsy: The Role of Positive Family History, Hypertension, Diabetes, and Body Mass Index.

Marco Oderda, Alessandro Dematteis, Giorgio Calleris, Adriana Conti, Daniele D'Agate, Marco Falcone, Alessandro Marquis, Gabriele Montefusco, Giancarlo Marra, Paolo Gontero

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Marco OderdaDivision of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Turin, Italy.ORCID 0000-0003-4681-888X
Alessandro DematteisDivision of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Turin, Italy.
Giorgio CallerisDivision of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Turin, Italy.
Adriana ContiDivision of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Turin, Italy.
Daniele D'AgateDivision of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Turin, Italy.
Marco FalconeDivision of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Turin, Italy.
Alessandro MarquisDivision of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Turin, Italy.
Gabriele MontefuscoDivision of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Turin, Italy.
Giancarlo MarraDivision of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Turin, Italy.
Paolo GonteroDivision of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Turin, Italy.
Fondazione Ricerca Molinette · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPSA density and an elevated PI-RADS score are among the strongest predictors of prostate cancer (PCa) in a fusion biopsy. Positive family history, hypertension, diabetes, and obesity have also been associated with the risk of developing PCa. We aim to identify predictors of the prostate cancer detection rate (CDR) in a series of patients undergoing a fusion biopsy.

methodsWe retrospectively evaluated 736 consecutive patients who underwent an elastic fusion biopsy from 2020 to 2022. Targeted biopsies (2-4 cores per MRI target) were followed by systematic mapping (10-12 cores). Clinically significant PCa (csPCa) was defined as ISUP score ≥ 2. Uni- and multi-variable logistic regression analyses were performed to identify predictors of CDR among age, body mass index (BMI), hypertension, diabetes, positive family history, PSA, a positive digital rectal examination (DRE), PSA density ≥ 0.15, previous negative biopsy status, PI-RADS score, and size of MRI lesion.

resultsThe median patients' age was 71 years, and median PSA was 6.6 ng/mL. A total of 20% of patients had a positive digital rectal examination. Suspicious lesions in mpMRI were scored as 3, 4, and 5 in 14.9%, 55.0%, and 17.5% of cases, respectively. The CDR was 63.2% for all cancers and 58.7% for csPCa. Only age (OR 1.04,

conclusionsIn a series of patients selected for a fusion biopsy, positive family history, hypertension, diabetes, or BMI are not predictors of PCa detection. PSA-density and PI-RADS score are confirmed to be strong predictors of the CDR.

Indexed as

Diabetes MellitusHypertensionProstatic NeoplasmsAgedBody Mass IndexHumansImage-Guided BiopsyMagnetic Resonance ImagingMaleProstate-Specific AntigenRetrospective StudiesProstate-Specific Antigenbody mass indexdiabetesfamily historyfusion biopsyhypertensionprostate cancerrisk factors

Identifiers

PMID37232832
PMCPMC10217714
OpenAlexW4376274021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.